The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
Open accessAbstract
Response criteria represent the standard by which the efficacy of therapeutic agents is determined in cancer trials. The most widely used criteria are based on the anatomic measurement of solid tumors. Because bone metastases are typically located in irregularly shaped bones and are difficult to measure with rulers, they have been previously considered unmeasurable disease. New developments in cancer response criteria have increased awareness of the importance of the response of bone metastases to therapy. The recently updated Response Evaluation Criteria in Solid Tumors (RECIST 1.1) now consider bone metastases with soft tissue masses > 10 mm to be measurable disease. Response criteria specific to bone metastases have been developed at The University of Texas MD Anderson Cancer Center (MDA criteria) and can be used to assess therapeutic response in numerous types of bone metastases. Functional imaging criteria, such as the recently developed Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) allow response to be measured in the absence of anatomic change through assessment of metabolic activity. As monitoring tumor response of bone metastases becomes more important in the management of cancer, so does the demand on radiologists and nuclear medicine physicians for accurate interpretation of the behavior of these lesions. This article reviews anatomic, bone, and metabolic response criteria, providing illustrations for the interpretation of therapy-induced change in bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Metastases in carcinoma.Analysis of 1000 autopsied cases
Abrams, H. L., Spiro, R., & Goldstein, N. (1950) · Cancer · doi:10.1002/1097-0142(1950)3:1<74::aid-cncr2820030111>3.0.co;2-7 · Cited by 1,865
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
(1992) · PubMed Central · doi:10.2967/jnumed.120.251744a · Cited by 1,172
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 705
Cited by
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Bone health in cancer: ESMO Clinical Practice Guidelines
Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 549
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Metadata
- Authors
- Costelloe, C. M., Chuang, H. H., Madewell, J. E., & Ueno, N. T.
- Venue
- Journal of Cancer
- Publisher
- Ivyspring International Publisher
- Published
- 2010
- Volume
- 1
- Pages
- 80-92
- ISSN
- 1837-9664 (ISSN-L)
- OpenAlex
- W2071433338
- Cited by
- 270
- References
- 51
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.